Hypoglycemic injection is speculated to be "weight loss needle", double the price

"Don't be hungry in one shot, full of satiety", "After using one, drop 5 pounds", "medical staff is also using itself" ...

Recently, domestic social platforms have frequently shared the "weight loss needle". A hypoglycemic injection called Smeglugin is being resold privately as a weight loss pill.

Smeglugin is the original research product of Novo and Nord. It was listed in the country in April 2021 and was included in medical insurance in December that year. The current approved indications in China were only type 2 diabetes. However, in the year of the listing, Simer Gulu peptide China's sales reached 46 million US dollars. In July of this year, sales of hospitals and pharmacies in some regional regional and pharmacies.

Affected by the shortage of supply, the price of the price rose, the 1.5ml Simeogupenicide injection was about 650 yuan per year. At present, some online platforms have reached about 850 yuan. "The price even soared to more than 1,000 yuan.

Jianzhi Bureau learned from Nuo and Noord that this hypoglycemic drug is indeed applying for weight loss indications in China. At present, it has entered the final stage of clinical trials. It is expected to submit a listing application next year.

On September 6, the State Drug Administration also approved the clinical application of the weight -loss indications of the Smeglugin tablets.

The hypoglycemic medicine becomes a "weight loss needle", just put on the stage?

Selling out of stock "weight loss magic medicine"

The Smegugu peptide injection is the second-generation GLP-1 receptor agonist developed by Novo Nord, which has a significant treatment effect in weight loss. In June 2021, the FDA has approved it as a weight loss pill.

It has been sold in China, but has not been approved for weight loss indications. Such a dislocation of this time makes it common for Smeglugin to be used.

Moreover, with the expansion of the "convenient" and "effective" grass remarks on social platforms, the use of the drug has quietly expanded from obese patients to thinned people. Under the stimulus of strong demand, some regional hospitals and pharmacies even sell out stocks.

Nuo and Nond did not directly respond to the current super adaptive medication, and only explained the supply shortage. The company said that the rapidly growing market demand and the logistics challenges caused by the global epidemic caused insufficient supply. The company will continue to expand Capacity guarantee clinical needs.

In fact, Smegugu peptide is not available.

The Chinese Pharmaceutical Examination Center intends to approve the adaptive crowd of the drug: the initial weight index (BMI) ≥28 kg/m2 patients; or between 24 kg/m2 to 28 kg/m2 Related patients with merging diseases.

For those who are fat or even normal, their benefits and risks are still unknown.

Smeglugin has become a weight loss pill from the cross -border of hypoglycemic drugs, and it still needs to emphasize that patients need "merging diseases".

In addition, "the medicine is three -point poison." The use of Smegugu peptide may cause gastrointestinal reactions, and even induce thyroid myelin -like cancer and pancreatitis. It is not advisable to take the medicine by itself.

Nuo and Nord do not seem to be in a hurry to lose weight.

Novo Norder said that Smegutin peptide tablets have completed the clinical trial of type 2 diabetes in China and submitted a listing application. Its weight loss indications have just been approved clinically.

But this does not affect the enthusiasm of transactions on social platforms.

Loss is a big business

Is the Chinese be fat or not?

The "Report on Nutrition and Chronic Diseases of Chinese Residents (2020)" released by the National New Affairs Office shows that the overweight and obesity rates of adult residents in my country are 34.3%and 16.4%, respectively, and more than 50%of adult residents are overweight or obese. Solving the problem of overweight or obesity has become an urgent need.

It is estimated that in 2025, the compliance market for weight loss pills is expected to exceed 12 billion yuan. However, there is only one legal weight loss drug in my country: African -prescription Olin, and its weight loss effect is not significant.

Therefore, Novo Nord does not have to worry about their unique weapons in the short term.

In 2014, Novo Nord was the first to develop the first generation of GLP-1 drugs in the world for the indications for weight loss. Soon, this weight loss needle was quietly popular in China. However, because Novo Nord has not completed the approval of Leralu peptide weight loss indications, the "weight loss needle" is only circulated in the underground market.

Globally, the patent of Lichelugin will expire after 2023. Domestic pharmaceutical companies have long been rubbing their fists, and pharmaceutical companies such as Cinda, Hengrui, East China Pharmaceutical have followed the development of Licula-peptide imitation pharmaceutical or other GLP-1 drugs. Among them, East China Pharmaceutical's Licolu peptide weight loss indication has submitted a listing application at the end of June, or it will become the first domestic variety of Licoluta peptides approved in China.

Under the wolf ring, in 2021, Novo and Noord launched the second-generation GLP-1 Sime Gulu peptide. In June of the same year, the FDA approved Smeglugin to be listed as a weight loss pill. Eat the GLP-1 weight loss market almost.

Smegugu peptide is an ultra -long -acting drug. It only needs to be administered once a week, and the weight loss effect is better. Phase III clinical results released by the New England Medical Journal showed that within 68 weeks of obesity or overweight adult patients with over 4,500 cases without type 2 diabetes, an average weight loss was 17%-18%.

In 2021, two drugs, Nuo and Nord's Litu peptide and Smeglugin, reached a growth rate of 50%with revenue of weight loss adaptive revenue.It is conceivable that after domestic GLP-1 drugs approved or oral GLP-1 drugs, the only market obstacles may only be production capacity.At that time, the phenomenon of private transactions on social platforms will inevitably intensify.

When will Nourn and Nord consider increasing production capacity?

Writing | Li Ao

Edit ｜ Jiang Yun Jia Ting

Operation | Xiaoxi

Illustration | Visual China

- END -